NDA 210136 · Braeburn
Brixadi
Buprenorphine · Subcutaneous · Partial Opioid Agonist
Priority reviewLast checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 23, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
512
125 Phase 3, 43 recruiting
FAERS reports
26,052
19,510 serious, 5,196 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. BRIXADI forms a liquid crystalline gel upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo‐embolic events, including life-threatening pulmonary emboli, if administered intravenously. (5.1) Because of the risk of serious harm or death that could result from intravenous self‐administration, BRIXADI is only available through a restricted program called the BRIXADI REMS. Healthcare settings and pharmacies that order and dispense BRIXADI must be certified in this program and comply with the REMS requirements. (5.2) WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; BRIXADI RISK EVALUATION AND MITIGATION STRATEGY See full prescribing information for...
What it is approved for
From the label in effect Dec 31, 2025.
BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. BRIXADI contains buprenorphine, a partial opioid agonist. BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. ( 1 ) BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. ( 1 )
Mechanism: BRIXADI contains buprenorphine, a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor.
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
7 products under this application
- BRIXADI · BUPRENORPHINE 96MG/0.27ML (356MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- BRIXADI · BUPRENORPHINE 32MG/0.64ML (50MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- BRIXADI · BUPRENORPHINE 16MG/0.32ML (50MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- BRIXADI · BUPRENORPHINE 128MG/0.36ML (356MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- BRIXADI · BUPRENORPHINE 64MG/0.18ML (356MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- BRIXADI · BUPRENORPHINE 24MG/0.48ML (50MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- BRIXADI · BUPRENORPHINE 8MG/0.16ML (50MG/ML) · SOLUTION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Buprenorphine" as an intervention, any sponsor and status, largest first.
- Houston Emergency Opioid Engagement SystemEnrolling by invitation
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03396276 · 3,000 participants (planned) · Start Apr 1, 2018 · Primary completion Aug 31, 2030
Drug: Suboxone · For: Opioid Use Disorder
Sites: Houston, Texas
- Emergency Department-Initiated Buprenorphine Validation Network TrialPivotal-lookingCompleted
Yale UniversityAcademic, hospital or other
NCT04225598 · 2,000 participants · Start Jul 8, 2020 · Primary completion Dec 6, 2024
Drug: CAM2038; Buprenorphine Sublingual Product · For: Opioid-use Disorder
Sites: Oakland, California; San Leandro, California; New Haven, Connecticut · 35 sites in all
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)Pivotal-lookingActive, not recruiting
NYU Langone HealthAcademic, hospital or other
NCT04464980 · 1,516 participants · Start Jun 8, 2021 · Primary completion Dec 31, 2026
Drug: SL-BUP; XR-BUP and 1 more · For: Opioid Use Disorder (OUD)
Sites: Little Rock, Arkansas; Tarzana, California; Bridgeport, Connecticut · 21 sites in all
- Buprenorphine and Integrated HIV Care EvaluationStatus unknown
The New York Academy of MedicineAcademic, hospital or other
NCT00124358 · 1,350 participants · Start Aug 2005
Drug: Buprenorphine · For: Opioid-Related Disorders; HIV Infections; AIDS
Sites: Tucson, Arizona; Oakland, California; San Francisco, California · 10 sites in all
- Starting Treatment With Agonist Replacement Therapies (START)Pivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT00315341 · 1,269 participants · Start Apr 2006 · Primary completion Aug 2010
Drug: Buprenorphine/naloxone; Methadone · For: Opiate-related Disorders
Sites: Los Angeles, California; Sacramento, California; San Francisco, California · 9 sites in all
- Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug UsersPivotal-lookingTerminated
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00270257 · 1,251 participants · Start May 2008 · Primary completion Jul 2012
Drug: Buprenorphine/Naloxone · For: HIV Infections; Opioid-Related Disorders
Sites: Hengzhou Town, China; Nanning, China; Ürümqi, China · 4 sites in all
- Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back PainPivotal-lookingCompleted
Braeburn PharmaceuticalsIndustry
NCT02946073 · 1,053 participants · Start Sep 2016 · Primary completion May 2018
Drug: buprenorphine · For: Chronic Lower Back Pain; Chronic Pain
Sites: Birmingham, Alabama; Hamilton, Alabama; Vestavia Hills, Alabama · 69 sites in all
- A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use DisorderPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT04375033 · 952 participants (planned) · Start Nov 3, 2020 · Primary completion Sep 30, 2028
Drug: Sublingual buprenorphine with naloxone; Injectable subcutaneous buprenorphine · For: Opioid Use Disorder
Sites: Tuscaloosa, Alabama; Phoenix, Arizona; Long Beach, California · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug dependence4,161
- overdose2,163
- drug abuse2,123
- pain2,065
- drug ineffective1,702
- death1,624
- toxicity to various agents1,608
- drug withdrawal syndrome1,547
- nausea1,336
- emotional distress1,253
- off label use1,108
- vomiting1,099
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 34 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 30 |
| 2010 | 83 |
| 2011 | 231 |
| 2012 | 384 |
| 2013 | 322 |
| 2014 | 355 |
| 2015 | 572 |
| 2016 | 572 |
| 2017 | 790 |
| 2018 | 1,367 |
| 2019 | 2,127 |
| 2020 | 2,121 |
| 2021 | 3,316 |
| 2022 | 3,529 |
| 2023 | 2,088 |
| 2024 | 3,019 |
| 2025 | 3,182 |
| 2026 | 1,920 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Brixadi (Buprenorphine)
2024 spending
$11.2M
Beneficiaries
1,795
7,546 claims
Per beneficiary
$6,242
$5,048.33 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $362,555 |
| 2024 | $11,205,219 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacy-based expansion of buprenorphine access.
Clark SA, Green TC, Rich JD · J Subst Use Addict Treat 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo L, Barrio G, Bravo MJ, et al. · BMJ 2017 · Meta-Analysis, Systematic Review
- Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial.
D'Onofrio G, Herring AA, Hawk KF, et al. · JAMA 2026 · Clinical Trial, Phase II, Comparative Study
- Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.
Degenhardt L, Clark B, Macpherson G, et al. · Lancet Psychiatry 2023 · Meta-Analysis, Systematic Review
- Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials.
Hickey TR, Costa GPA, Oliveira D, et al. · Reg Anesth Pain Med 2026 · Systematic Review, Meta-Analysis
- Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Lofwall MR, Walsh SL, Nunes EV, et al. · JAMA Intern Med 2018 · Comparative Study, Randomized Controlled Trial
Sponsor: Braeburn
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.